June 25, 2017 7:52 PM ET


Company Overview of Tasmanian Alkaloids Pty Ltd

Company Overview

Tasmanian Alkaloids Pty Ltd. manufactures controlled substances and provides medicinal opiates from patented poppy varieties grown on the farms of Tasmania. It offers agricultural, and chemical and analytical research and development services. The company’s products are used in pharmaceuticals. It distributes its products through a network of distributors and agents worldwide. The company was founded in 1975 and is based in Westbury, Australia. Tasmanian Alkaloids Pty Ltd. operates as a former subsidiary of Johnson & Johnson.

160 Birralee Road

Westbury, TAS 7303


Founded in 1975


61 3 6393 5202


61 3 6393 1575

Key Executives for Tasmanian Alkaloids Pty Ltd

Managing Director
Compensation as of Fiscal Year 2016.

Tasmanian Alkaloids Pty Ltd Key Developments

AusCann Group Holdings Signs Heads of Agreement to Form an Exclusive Strategic Partnership with Tasmanian Alkaloids

AusCann Group Holdings Ltd. announced it has signed a Heads of Agreement to form an exclusive strategic partnership with Tasmanian Alkaloids Pty Ltd. AusCann and Tasmanian Alkaloids will work together to establish cultivation, manufacturing and distribution operations for medicinal cannabis in Australia and overseas. Through the strategic partnership, AusCann will have access to Tasmanian Alkaloids' wealth of expertise. Jointly, the two companies will secure a license to cultivate and manufacture medicinal cannabis in Tasmania. The Tasmanian license will be in addition to AusCann's current medical cannabis cultivation license granted last week by the Office of Drug Control. AusCann will continue to import product from its partner Canopy Growth Corporation.

SK Capital Eyeing Tasmanian Alkaloids

SK Capital Partners may acquire Tasmanian Alkaloids Pty Ltd. (TA). The company looks set to be sold to SK Capital. On March 9, 2016, TA's staff was told that SK Capital was taking over a potential deal to be finalized in June 2016. Johnson & Johnson (NYSE:JNJ) said that it would not comment until the sale was complete, Tasmania Alkaloids said their expectation was ‘business as usual’. Tasmania Alkaloids Chief Executive Officer, Keith Rice said he was keen to meet SK Capital's representatives when they visited in April 2016. Keith Rice said, “It is a private investment firm with a focus on specialty materials, chemicals and healthcare. Its portfolio of companies generates revenues of over $8 billion annually, and it employs 9,000 people. We've not found out a great deal about it and I imagine its footprint goes beyond the United States. We understand that representatives of the company will be out here in the not too distant future, and naturally, we will be looking forward to meeting with them and seeing what their plans are for the future of the industry in Tasmania.”

Similar Private Companies By Industry

Company Name Region
4G Vaccines Pty Ltd. Asia
Advent Pharmaceuticals Pty Ltd. Asia
AFT Pharmaceuticals Pty Ltd Asia
Anagen Pty Limited Asia
Ascend Biopharmaceuticals Ltd. Asia

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Tasmanian Alkaloids Pty Ltd, please visit www.tasalk.com.au. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.